Results 211 to 220 of about 222,862 (245)
Some of the next articles are maybe not open access.
2019
Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and
Fulwah Yahya, Alqahtani +4 more
openaire +2 more sources
Paclitaxel is the first microtubule-stabilizing agent identified and considered to be the most significant advance in chemotherapy of the past two decades. It is considered one of the most widely used antineoplastic agents with broad activity in several cancers including breast cancer, endometrial cancer, non-small-cell lung cancer, bladder cancer, and
Fulwah Yahya, Alqahtani +4 more
openaire +2 more sources
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1994
Paclitaxel is a novel antineoplastic that effects cytotoxicity by promoting intracellular tubulin polymerization and stabilizes abnormal microtubule structures against depolymerization. Although its clinical development had been hampered by misconceptions about its pharmacology, its scarcity, difficulties extracting it from its natural source ...
D R, Kohler, B R, Goldspiel
openaire +2 more sources
Paclitaxel is a novel antineoplastic that effects cytotoxicity by promoting intracellular tubulin polymerization and stabilizes abnormal microtubule structures against depolymerization. Although its clinical development had been hampered by misconceptions about its pharmacology, its scarcity, difficulties extracting it from its natural source ...
D R, Kohler, B R, Goldspiel
openaire +2 more sources
The clinical development of paclitaxel and the paclitaxel/carboplatin combination
European Journal of Cancer, 1998Paclitaxel and carboplatin have nonoverlapping toxicities with a broad range of clinical activity. The combination of escalating dose paclitaxel and carboplatin dosed to a fixed area under the curve (AUC) was explored in a series of phase I studies.
Gary Schwartz +6 more
openaire +3 more sources
iRGD‐paclitaxel conjugate nanoparticles for targeted paclitaxel delivery
Drug Development Research, 2019AbstractPaclitaxel (PTX) is a chemotherapeutic agent which shows antitumor activities against a broad spectrum of cancers. Yet, the current formulation of PTX used in clinic may cause a number of adverse reactions, which significantly limit its application.
Xiangjian Xu +7 more
openaire +3 more sources
Improvement of paclitaxel-induced neuropathy by substitution of docetaxel for paclitaxel
Gynecologic Oncology, 2003Although the combination of paclitaxel and carboplatin has a better therapeutic index than the combination of paclitaxel and cisplatin, peripheral neuropathy often occurs and remains the most chronic toxicity of this therapy.Six patients with ovarian or peritoneal carcinoma who developed grade 2 peripheral neuropathy during chemotherapy with paclitaxel
Peter G. Rose +4 more
openaire +3 more sources
Metabolism of paclitaxel in mice
Anti-Cancer Drugs, 2003Previous mass balance studies in humans and mice have shown that the fecal and urinary recovery of paclitaxel and known metabolites (3' -hydroxypaclitaxel, 6alpha-hydroxypaclitaxel and 3',6alpha-dihydroxypaclitaxel) was not complete. Obviously this discrepancy is caused by the existence of other yet unknown metabolites.
Ingrid A M Oomen +5 more
openaire +4 more sources
2009
Publisher Summary This chapter introduces paclitaxel and describes its prepration methods, physical properties, analysis methods, stability, pharmacokinetics, and metabolism. Paclitaxel is an antineoplastic agent that is highly effective against ovarian and breast cancer.
Saurabh Jauhari +2 more
openaire +3 more sources
Publisher Summary This chapter introduces paclitaxel and describes its prepration methods, physical properties, analysis methods, stability, pharmacokinetics, and metabolism. Paclitaxel is an antineoplastic agent that is highly effective against ovarian and breast cancer.
Saurabh Jauhari +2 more
openaire +3 more sources
Alternative formulations of paclitaxel
Cancer Treatment Reviews, 1997Paclitaxel, a novel antitumour agent, is active clinically against advanced ovarian and breast cancer and under investigation for various other cancers. One of the problems associated with the intravenous administration of paclitaxel is its low solubility in water.
J. M. Meerum Terwogt +4 more
openaire +4 more sources
Expert Opinion on Pharmacotherapy, 2002
The last decade witnessed the introduction of exciting new chemotherapeutic agents. Among these, paclitaxel emerged as one of the most powerful compounds. Paclitaxel promotes the polymerisation of tubulin, thereby causing cell death by disrupting the normal microtubule dynamics required for cell division and vital interphase processes.
Maurie Markman, Tarek Mekhail
openaire +3 more sources
The last decade witnessed the introduction of exciting new chemotherapeutic agents. Among these, paclitaxel emerged as one of the most powerful compounds. Paclitaxel promotes the polymerisation of tubulin, thereby causing cell death by disrupting the normal microtubule dynamics required for cell division and vital interphase processes.
Maurie Markman, Tarek Mekhail
openaire +3 more sources
Journal of Clinical Oncology, 2006
10758 Background: For the past fifteen years many clinical trials have demonstrated that paclitaxel therapy could generate 30% to 60% response rate in patients with breast cancer. Recent clinical trials indicated that when used as control, paclitaxel therapy only produced 20% response rate in patients with breast cancer.
G. Sulemanjee, T. L. Cao, S. Ristzert
openaire +2 more sources
10758 Background: For the past fifteen years many clinical trials have demonstrated that paclitaxel therapy could generate 30% to 60% response rate in patients with breast cancer. Recent clinical trials indicated that when used as control, paclitaxel therapy only produced 20% response rate in patients with breast cancer.
G. Sulemanjee, T. L. Cao, S. Ristzert
openaire +2 more sources